This site is intended for healthcare professionals
  • Home
  • /
  • Clinical trials
  • /
  • Uncategorised Disease
  • /
  • Continued Efficacy and Safety Monitoring of Solane...
Clinical trial

Continued Efficacy and Safety Monitoring of Solanezumab, an Anti-Amyloid ? Antibody in Patients with Alzheimer�s Disease

Read time: 1 mins
Last updated:23rd Dec 2010
The primary objective of the study is to assess the safety of solanezumab in Alzheimer�s disease (AD) patients during 24 months of open-label treatment following completion of 18 months of treatment with solanezumab or placebo in a double-blind registration study (H8A-MC-LZAM [LZAM] or H8A-MC-LZAN [LZAN], �feeder studies�) through analysis of AEs, vital signs, laboratory evaluations, electrocardiograms (ECGs), and MRIs.
Category Value
Study start date 2010-12-23

View full details